Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
OVERVIEW
HTA Ignite: Real-World, Real-Impact
The ME Pharmacoeconomics & Drug Policy Summit, under the core theme “HTA Ignite: Real-World,Real-Impact,” highlights evidence-based assessments and the development of transparent frameworksfor value-driven healthcare decisions across the Middle East. The event will gather regulators, healtheconomists, payers, providers, and industry leaders to share insights, exchange strategies, and explore innovative approaches for enhancing patient outcomes while maximizing resource efficiency.
The summit will demonstrate how Health Technology Assessment (HTA) harnesses Real-World Data (RWD) to produce actionable Real-World Evidence (RWE) by assessing the clinical, economic, and societal impact of therapies, HTA enables value-based pricing, improves access to advanced treatments, and promotes sustainable healthcare practices. Integrating RWE with HTA ensures that policies are both practical and patient-centered, driving long-term improvements in healthcare delivery across the region.
Who Attended 2025 Summit
Conference Key Facts
WHO SHOULD ATTEND
- Regulatory authorities
- Pharmacoeconomists
- Health Economists
- Health Technology Assessment Specialists
- Payers & Health Insurance – Drug pricing & Reimbursement Departments
- Healthcare providers
- Pharma Industry: Market access teams
- Pharmacists
- Real-World Evidence (RWE) and Real-World Data (RWD) experts
- HEOR (Health Economics & Outcomes Research) professionals
- Pricing and policy strategists
- National HTA agencies and committees
KEY BENEFITS OF ATTENDING
- Highlight future opportunities and challenges in developing the healthcare and research economy in the GCC countries
- Discuss the novel approaches to value assessment, achieving cost effective healthcare solutions and access to innovative medicines in the GCC
- Understanding the principles of outcome based healthcare and evidence based medication
- Reviewing pharmacoeconomics and outcomes research strategies
- Exploring the real world data, the burden of disease and HTA to make proper assessments and support decision making
Summit chairman
Ahmed Al Jedai
Founding President, Saudi Society of Clinical Pharmacy, Professor, Colleges of Medicine and Pharmacy, Alfaisal University, Consultant Clinical Pharmacist, Solid Organ Transplant, Ministry of Health, KSA
SUMMIT VICE CHAIR
Mohammed Alshennawi
General Director, General Administration of Pharmaceutical Care, Ministry of Health, KSA
ORGANIZING COMMITTEE CHAIR
Wejdan I. Aburas
Director, Drug Policy and Regulation, Senior Cardiology Clinical Pharmacist, Therapeutic Affairs Deputyship, Ministry of Health, KSA
Scientific Committee Chair
Hajer Al-Mudaiheem
Board Member, Saudi Society of Clinical Pharmacy (SSCP), KSA
Strategic Partner
AN INITIATIVE BY
Summit Packages
2-Days Summit Access
Physicians, Regulatory Authorities, Health Economists, Hospital and Community Pharmacists
Pharmaceutical Companies and Vendors
THANKS TO OUR SPONSORS
Click on the logo to view the company profile, or visit the sponsor’s homepage.
Platinum Sponsors
Amgen is a global biotechnology company focused on discovering, developing, and delivering innovative medicines for serious diseases, with a clear mission to improve patient outcomes while supporting sustainable healthcare systems.
Amgen continues to advance a strong portfolio of therapies across high-burden diseases, including cardiovascular conditions, obesity and related diseases, rare diseases, inflammation, and cancer—driven by science and a commitment to meaningful clinical impact.
Amgen partners with healthcare stakeholders to generate and apply real-world evidence, supporting value-based healthcare decisions and improving patient access to innovative therapies
About Roche Founded in 1896, Roche is the world’s largest biotech company and a global leader in in-vitro diagnostics. The company combines strengths in Pharma and Diagnostics with clinical data to drive personalised healthcare. In the Middle East, Roche has provided pharmaceutical and diagnostic expertise for over 85 years across 15 countries. Learn more at www.roche-middleeast.com.
Since 1947, Roche has served as a strategic partner to the healthcare sector in the Kingdom of Saudi Arabia.
By establishing a fully-fledged legal entity and its office in Riyadh, Roche is committed to fostering long-term national partnerships that prioritize innovation and local capacity building.
Roche’s initiatives focus on enhancing the efficiency of the healthcare ecosystem in direct alignment with the objectives of Saudi Vision 2030 and the National Health Transformation Program, ensuring sustainable access to world-class diagnostic and therapeutic solutions for all patients in the Kingdom.
Gold Sponsors
We innovate across the full spectrum of healthcare solutions today to uniquely position us for the breakthroughs of tomorrow. As a focused healthcare company, with expertise in Innovative Medicine and MedTech, there are specific areas where we uniquely impact health in a way that only we can.
Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow.
Our diverse product portfolio spans multiple areas, where patient need is high and our expertise is deep:
• Oncology
• Immunology
• Neuroscience
• Cardiopulmonary
Through rigorous research, strategic collaborations, and a sustained focus on patient outcomes, we deliver solutions that support healthcare professionals and strengthen standards of care.
Our antifungal portfolio includes REZZAYO® (rezafungin), a next-generation echinocandin developed to provide once-weekly dosing for adults with invasive candidiasis.
This innovation reflects our broader mission: to bring clinically meaningful advancements to complex therapeutic areas while fostering reliability, quality, and scientific excellence across the healthcare ecosystem.
Silver Sponsors
Media Partners
